Skip to main content

Table 2 Patient characteristics

From: GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment

Pathological response

All patients (pCR + Non-pCR)

pCR

Non-pCR

Age (years)

 Median (range)

61.7 (33–69)

65.3 (38–69)

58.1 (34–68)

Subtype

 TN

6

3

3

 Her2+

11

9

2

 ESR+/Her2-

3

2

1

Tumor size stage

 T0

1

1

0

 T1

13

10

3

 T2

1

0

1

 T3

5

3

2

Nodal stage

 N0

5

3

2

 N1

10

9

1

 N2

2

2

0

 N3

3

2

1

Total

20

14

6

  1. ESR Estrogen Receptor, pCR pathological Complete Response, TN triple negative